The FDA granted approval to azacitidine tablets (Onureg, Celgene) for treatment of patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or CR with incomplete blood count recovery (CRi) after intensive induction chemotherapy and are not able to complete intensive curative therapy.
“Continued treatment with Onureg demonstrated an overall survival benefit in adults with AML who had achieved first complete remission in the QUAZAR AML-001 study, and, notably, it